Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Depreciation and Depletion (2016 - 2021)

Kiora Pharmaceuticals (KPRX) has disclosed Depreciation and Depletion for 7 consecutive years, with $4786.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Depreciation and Depletion rose 70.56% year-over-year to $4786.0, compared with a TTM value of $20296.0 through Dec 2021, up 141.65%, and an annual FY2024 reading of $5000.0, down 83.33% over the prior year.
  • Depreciation and Depletion was $4786.0 for Q4 2021 at Kiora Pharmaceuticals, roughly flat from $4807.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $9632.0 in Q3 2018 and bottomed at $817.0 in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $5344.4, with a median of $5243.5 recorded in 2017.
  • The sharpest move saw Depreciation and Depletion surged 5300.0% in 2017, then tumbled 87.75% in 2020.
  • Year by year, Depreciation and Depletion stood at $5680.0 in 2017, then rose by 17.41% to $6669.0 in 2018, then dropped by 0.01% to $6668.0 in 2019, then tumbled by 57.92% to $2806.0 in 2020, then soared by 70.56% to $4786.0 in 2021.
  • Business Quant data shows Depreciation and Depletion for KPRX at $4786.0 in Q4 2021, $4807.0 in Q3 2021, and $6354.0 in Q2 2021.